Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Share

Tübingen, Germany, February 15, 2024

Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).

Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing. With the introduction of cisplatin as a treatment option in the late 1970s, most men with metastatic testicular cancer are cured, with a 30–60 year life expectancy after treatment. Ototoxicity is a typical and severe side effect of cisplatin treatment and is a consequence of irreversible damage to the sensory cells in the inner ear, the so-called outer hair cells. While ototoxicity may have been an unavoidable trade-off for a cancer cure to date, clinical hearing loss comes with considerable negative impacts for survivors, including communication problems, heightened fatigue, reduced social interaction, and an increased long-term risk of developing dementia. In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.

In the double-blind, randomized PROHEAR-Study, patients with testicular cancer receive transtympanic injections of ACOU085 in one ear and a placebo in the contralateral ear prior to each chemotherapy cycle, as such each patient serves as his own control. The PROHEAR-Study is being conducted at major university clinics across Germany and has been formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO).

“The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable” said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

About Acousia Therapeutics GmbH

Acousia Therapeutics GmbH is a privately held, clinical-stage biotech company based in Tübingen, Germany. The company is dedicated to the identification of small molecules for the effective prevention and treatment of different hearing loss etiologies. Acousia is focused on the development of proprietary drug candidates, which are designed to affect the sensory outer hair cells (OHC) in the cochlea of the inner ear. The unique dual mode of action of its small-molecule Kv7.4 activators combines acute functional OHC enhancement and sustained OHC protection and aims to both enhance and preserve a patient’s natural hearing. Acousia Therapeutics develops drugs for both local and systemic administration.

Contacts

Tim Boelke, M.D.
boelke@acousia.com
www.acousia.com

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Severe Vulnerabilities Discovered in Software to Protect Internet Routing11.4.2024 16:51:22 CEST | Pressmeddelande

A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key Infrastructure (RPKI). RPKI is an Internet standard meant to protect Internet traffic from being hijacked by hackers. By now, all affected vendors provided patches for their products. The vulnerabilities could have had devastating consequences: Internet hijacks have already been exploited, e.g., for phishing passwords and other sensitive information, tricking certificate authorities into issuing fraudulent Web certificates, stealing cryptocurrency, distributing malware, and poisoning caches of DNS servers.

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment10.4.2024 11:00:00 CEST | Press release

The launch in Germany through its step-down subsidiary betapharm marks Dr. Reddy's entry into digital therapeutics in Europe. Nerivio® is the first REN (wearable, FDA-cleared, and CE-marked for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Nerivio® is worn on the upper arm during treatment and controlled by a smartphone app, making it comfortable and portable. Starting with Germany, followed by Spain and the UK, Dr. Reddy's plans to further increase access to Nerivio® in European countries.

CIVIS Media Prize 2024 | 25 productions nominated, 6 podcasts for public voting9.4.2024 11:00:00 CEST | Pressmeddelande

9.4.2024 Cologne (ots) | CIVIS Media Prize 2024 – 25 nominees for Europe's most important media prize for integration and cultural diversity have been shortlisted: Candidates for the CIVIS Media Prize include entries from Aamu Film Company, ACB Stories, ARTE, Deutschlandradio, electronic media school, La Fémis, Filmakademie Baden-Württemberg, funk, France 2, HFF München, hr, MADE IN GERMANY Filmproduktion, MDR, NDR, RTL+, (SIC) Pictures, SWR, Undone, UFA Documentary, WDR and ZDF. Festival films could also be submitted for the first time. The complete list of nominees can be found here as well as in the press section of the CIVIS Media Foundation website. Close to 900 productions from television, radio and the Internet were submitted for the CIVIS Competition 2024. For the first time, they came from all 27 EU member states and Switzerland. The productions, each in their own specific way, deal with highly topical issues such as war, flight, labour migration, racism, anti-Semitism, antizi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye